

# MOLECULAR AND BIOCHEMICAL TOXICOLOGY

FIFTH EDITION



EDITED BY  
ROBERT C. SMART AND ERNEST HODGSON

**WILEY**



## **Molecular and Biochemical Toxicology**



# Molecular and Biochemical Toxicology

Fifth Edition

*Edited by Robert C. Smart and Ernest Hodgson*

*North Carolina State University  
Raleigh, NC, USA*

**WILEY**

This edition first published 2018  
© 2018 John Wiley & Sons, Inc.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at <http://www.wiley.com/go/permissions>.

The right of Robert C. Smart and Ernest Hodgson to be identified as the editors of this work has been asserted in accordance with law.

*Registered Offices*

John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA

*Editorial Office*

111 River Street, Hoboken, NJ 07030, USA

For details of our global editorial offices, customer services, and more information about Wiley products visit us at [www.wiley.com](http://www.wiley.com).

Wiley also publishes its books in a variety of electronic formats and by print-on-demand. Some content that appears in standard print versions of this book may not be available in other formats.

*Limit of Liability/Disclaimer of Warranty*

The publisher and the authors make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for every situation. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of experimental reagents, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each chemical, piece of equipment, reagent, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. The fact that an organization or website is referred to in this work as a citation and/or potential source of further information does not mean that the author or the publisher endorses the information the organization or website may provide or recommendations it may make. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising herefrom.

*Library of Congress Cataloging-in-Publication Data*

Names: Smart, Robert C., 1954– editor. | Hodgson, Ernest, 1932– editor.

Title: Molecular and biochemical toxicology / edited by, Dr. Robert C. Smart,

North Carolina State University, Raleigh, NC, USA, Dr. Ernest Hodgson,

North Carolina State University, Raleigh, NC, USA.

Description: Fifth edition. | Hoboken, NJ : Wiley, [2018] | Includes bibliographical references and index. |

Identifiers: LCCN 2017024306 (print) | LCCN 2017024681 (ebook) |

ISBN 9781119042426 (pdf) | ISBN 9781119042433 (epub) |

ISBN 9781119042419 (hardback)

Subjects: LCSH: Biochemical toxicology.

Classification: LCC RA1219.5 (ebook) | LCC RA1219.5 .I58 2018 (print) | DDC 615.9–dc23

LC record available at <https://lccn.loc.gov/2017024306>

Cover design by Wiley

Cover image: © maxuser/Shutterstock

Set in 10/12pt Warnock by SPi Global, Pondicherry, India

Printed in the United States of America

## Contents

**Preface** *xxix*

**List of Contributors** *xxxi*

### **Section 1 Introduction** *1*

#### **1 Molecular and Biochemical Toxicology: Definition and Scope** *3*

*Ernest Hodgson and Robert C. Smart*

##### 1.1 Introduction *3*

##### 1.2 Sources of Information *5*

##### 1.3 Toxicology *5*

##### 1.4 Molecular and Cellular Toxicology *6*

##### 1.5 Proteomics and Metabolomics *8*

##### 1.6 Role of Molecular, Cellular, and Biochemical Toxicology: Implications for Risk Assessment *8*

##### 1.7 Conclusions *9*

Suggested Reading *9*

### **Section 2 Techniques in Biochemical and Molecular Toxicology** *11*

#### **2 Molecular Techniques for the Study of Gene Function** *13*

*Yoshiaki Tsuji and Robert C. Smart*

##### 2.1 Applicability of Molecular Techniques to Toxicology *13*

##### 2.2 Overview of Genes, Chromatin, and Their Relationship *15*

##### 2.2.1 The Genetic Code and Flow of Genetic Information *15*

##### 2.2.2 Chromatin and Gene Regulation *18*

##### 2.3 Approaches to Characterize the Functions of Genes *20*

##### 2.3.1 Molecular Cloning and Plasmid Vectors *20*

##### 2.3.2 Construction of cDNA and Genomic Libraries *23*

##### 2.3.3 Eukaryotic Expression Systems *26*

2.3.3.1	Gene Delivery into Mammalian Cells: Plasmid Vectors	26
2.3.3.2	Inducible Expression Vector: The TET-Inducible System	28
2.3.3.3	Gene Delivery into Mammalian Cells: Viral Vectors	30
2.4	Gene Targeting Technologies	31
2.4.1	Gene Silencing by Knockdown with Small Interfering RNA (siRNA)	31
2.4.2	Protein-Guided Gene Targeting: ZFN and TALEN	33
2.4.3	RNA-Guided Gene Targeting: The CRISPR/CAS System	34
2.5	Analysis of Gene Expression and Regulatory Mechanisms	35
2.5.1	Southern and Northern Blot Analyses	35
2.5.2	Western Blot Analysis	37
2.5.3	Polymerase Chain Reaction (PCR)	37
2.5.4	Reverse Transcription PCR (RT-PCR) and Real-Time PCR	39
2.5.5	Promoter Deletion Analysis/Reporter Gene Assays	40
2.5.6	Electrophoretic Mobility Shift Assay (EMSA) and Pulldown with Biotinylated Probe and Streptavidin Beads	41
2.5.7	Chromatin Immunoprecipitation (ChIP) and RNA Immunoprecipitation (RIP)	42
2.5.8	Microarrays and RNA Sequencing	44
2.6	Methods to Evaluate Gene Function in an Animal Model	45
2.6.1	Procedure for Making Transgenic Mice Using Zygote Injection	45
2.6.2	General Procedure for Making Knockout Mice Using Embryonic Stem Cells	47
2.6.3	Making Conditional Knockout Mice Using the Cre/loxP Recombinant System	49
2.6.4	Making Knockout Mice Using the CRISPR/CAS9 System	52
	References	54
	Suggested Reading	54
<b>3</b>	<b>Transcriptomics</b>	<b>55</b>
	<i>B. Alex Merrick</i>	
3.1	Introduction	55
3.1.1	The Transcriptome	55
3.2	Cellular Organization and the Transcriptome	58
3.2.1	Transcription	58
3.2.2	Genes and Transcripts: Traits and Functions	60
3.2.3	Annotation of the Transcriptome	62
3.2.4	Annotation	62
3.3	RNA Isolation	62
3.3.1	Sample Collection for Transcriptome Analysis	62
3.3.2	RNA Isolation Methods	63
3.3.3	Quantitative and Qualitative RNA Measures	63
3.4	Platforms for Transcriptome Analysis: Microarrays	64
3.4.1	Microarray Platforms	64



3.4.2	How Is Microarray Analysis Performed?	65
3.4.3	Data Normalization	68
3.4.4	Differential Expression and Data Analysis	69
3.4.5	Genomes, Transcriptomes, and Microarrays	69
3.4.6	Application of Microarrays to Toxicogenomics	71
3.5	RNA-seq: NextGen Sequencing of the Transcriptome	72
3.5.1	Introduction	72
3.5.2	DNA Sequencing	72
3.5.3	RNA-seq	73
3.5.4	Advantages and Disadvantages of RNA-seq	75
3.5.5	RNA-seq Analysis	76
3.5.6	Choosing RNA-seq or Microarray	78
3.5.7	Application of RNA-seq to Chemical Toxicity	79
3.6	Validation of Transcriptome Analysis	81
3.7	Analysis of Gene Expression Data	82
3.7.1	Introduction	82
3.7.2	Hierarchical Clustering	82
3.7.3	Principal Component Analysis (PCA)	85
3.7.4	Biological Functional Analysis	85
3.7.5	Pathway Analysis	86
3.8	Summary	86
	References	87
<b>4</b>	<b>Proteomics</b>	<b>91</b>
	<i>Michael S. Bereman</i>	
4.1	Introduction to Proteomics	91
4.2	Mass Spectrometry	94
4.2.1	Fundamentals of Mass Measurement	94
4.2.2	Sample Preparation in Bottom-Up Proteomics	98
4.2.3	Liquid Chromatography: An Essential Tool	99
4.2.4	Ionization Methods	100
4.2.5	Tandem Mass Spectrometry	102
4.2.6	Bioinformatic Pipeline	106
4.3	Quantitation of Proteins by LC-MS/MS	107
4.3.1	Label-Free Quantitation	107
4.3.2	Metabolic Labeling	108
4.3.3	Isobaric Tags	109
4.4	Emerging Research Areas in Proteomics	109
4.4.1	Posttranslational Modifications	109
4.4.2	Interactomics	111
4.4.3	Toxicoproteomics	111
4.5	Summary	112
	Suggested Reading	112

<b>5</b>	<b>Metabolomics</b>	<b>115</b>
	<i>Susan C. J. Sumner, Wimal Pathmasiri, James E. Carlson, Susan L. McRitchie, and Timothy R. Fennell</i>	
5.1	Introduction	115
5.2	Endogenous and Exogenous Metabolites	116
5.2.1	Endogenous Metabolites	116
5.2.2	Exogenous Metabolites	116
5.2.3	Exposome	117
5.3	Study Design and Experimental Considerations	117
5.3.1	Study Design Considerations	117
5.3.2	Sample Collection, Storage, and Processing Considerations	119
5.4	Applications of Metabolomics	120
5.4.1	Behavior and Diagnosis	120
5.4.2	Drug Exposure and Adverse Outcomes	121
5.4.3	Chemical Exposure	121
5.4.4	Linking <i>In Utero</i> Exposure to Birth and Health Outcomes	122
5.5	Technologies for Targeted and Broad-Spectrum Metabolomics	122
5.5.1	Nuclear Magnetic Resonance (NMR) Spectroscopy for Targeted and Broad-Spectrum Metabolomics	123
5.5.2	Mass Spectrometry for Targeted and Broad-Spectrum Metabolomics	124
5.5.2.1	Targeted Mass Spectrometry Metabolomics	124
5.5.2.2	Stable Isotope Resolved Metabolomics (SIRM) and Metabolic Flux Analysis	125
5.5.2.3	Broad-Spectrum Mass Spectrometry Metabolomics	125
5.5.2.4	Coulometric Methods for Neurotransmitter Detection	126
5.6	Statistical and Multivariate Analysis and Pathway Mapping	127
5.6.1	Standard Statistical Approaches	127
5.6.2	Multivariate Analysis	127
5.6.3	Quality Control	128
5.6.4	Mapping Metabolites to Biochemical Pathways	129
5.6.5	Modeling Approaches	129
5.7	Summary	130
	Acknowledgment	130
	References	131
<b>6</b>	<b>Cellular Techniques</b>	<b>135</b>
	<i>Sharon A. Meyer and Barbara A. Wetmore</i>	
6.1	Introduction	135
6.2	Cellular Studies in Intact Tissue	137
6.2.1	Whole Animal Studies	137
6.2.2	Tissue Slices	138
6.3	Studies with Dispersed, Isolated Cells	138

6.3.1	Tissue Digestion and Cell Separation	138
6.3.2	Limited Maintenance in Defined Media	141
6.3.3	Long-Term Suspension Culture	141
6.4	Monolayer Cell Culture	142
6.4.1	Propagation of Primary and Passaged Cultures	142
6.4.2	Immortalized Cells	143
6.4.2.1	Cell Line Contamination	144
6.4.3	Modifications to Monolayer Cell Culture	146
6.4.3.1	Reconstructed/Bioengineered Tissue	146
6.4.4	Stem Cell Cultures	147
6.5	Observation of Cultured Cells	148
6.6	Indicators of Toxicity	149
6.6.1	Intact Tissue	149
6.6.2	Cell Culture	149
6.6.3	High-Throughput Cellular Systems	151
6.7	Important Considerations and Advances	152
6.7.1	Considerations in <i>In Vitro</i> Cytotoxicity Assessments	152
6.7.2	Experimental Confounders to Interpretation of <i>In Vitro</i> Data	153
6.7.3	Relating <i>In Vitro</i> Effects to <i>In Vivo</i> Exposures	154
6.8	Replacement of Animal Testing with Cell Culture Models	155
6.9	Conclusion	157
	Suggested Reading	157
	Journals	158

## 7 Basic Concepts of Molecular Epidemiological Research

### Methods 159

*Cathrine Hoyo, David A. Skaar, and Randy L. Jirtle*

7.1	Introduction	159
7.2	Molecular Epidemiology	160
7.2.1	Definition	160
7.2.2	Criteria for Biomarker Identification and Validation	162
7.2.3	Biomarker Development and Validation	162
7.2.3.1	Biomarker Development	162
7.2.3.2	Validity	162
7.2.3.3	Reliability	163
7.2.3.4	An Example	163
7.3	Descriptive Epidemiologic Study Designs	164
7.3.1	Descriptive Epidemiology Is Used to Identify Patterns of Disease and Exposure	164
7.3.2	Disease and Death Occurrence Measurement	165
7.3.3	Example of Descriptive Study	166
7.4	Analytic Epidemiologic Studies	167
7.4.1	Observational Studies	167

7.4.1.1	Cross-Sectional Studies	167
7.4.1.2	Case–Control Studies	169
7.4.1.3	Cohort Studies	171
7.5	Experimental Studies	173
7.5.1	Analytic Approach	173
7.5.2	Experimental Study Example	173
7.6	Inferring Causality from Molecular Epidemiologic Data	174
7.6.1	Evidence of Statistical Associations and Apparent Dose–Response	175
7.6.1.1	Statistical Association	175
7.6.1.2	Random Error in Estimating the Magnitude of Associations	175
7.6.1.3	Dose–Response	176
7.6.1.4	Interaction or Effect Modification	176
7.6.1.5	Mediation	177
7.6.1.6	Confounding	177
7.6.1.7	Information Bias	179
7.6.1.8	Selection Bias	179
7.6.1.9	Statistical Power	180
7.6.2	Temporal Sequence	180
7.6.2.1	An Example	181
7.6.3	Replicable Associations	181
7.6.3.1	An Example	181
7.6.4	Biological Plausibility of Associations Observed	181
7.6.4.1	An Example	182
7.7	Summary	182
	References	183
	Suggested Reading	184
	Reading Materials Related to Examples	184

### **Section 3 Mechanisms in Molecular and Biochemical Toxicology 187**

<b>8</b>	<b>Phase I and Phase II Metabolism and Metabolic Interactions: A Summary</b>	<b>189</b>
	<i>Ernest Hodgson</i>	
8.1	Introduction	189
8.2	Metabolic Enzymes	189
8.3	Phase I Reactions	191
8.3.1	Monooxygenases	191
8.3.2	Non-Microsomal Oxidations	194
8.3.3	Cooxidation by Cyclooxygenase	195
8.3.4	Reduction Reactions	195

8.3.5	Hydrolysis	195
8.4	Phase II Reactions	196
8.4.1	Glucuronide Conjugation	197
8.4.2	Sulfate Conjugation	197
8.4.3	Methyltransferases	197
8.4.4	Glutathione <i>S</i> -Transferases (GSTs) and Mercapturic Acid Formation	197
8.4.5	Acylation Reactions	198
8.4.6	Amino Acid Conjugation	198
8.5	Reactive Metabolites	199
8.6	Factors Affecting Metabolism	200
8.6.1	Introduction	200
8.6.2	Gender, Genetics, and Polymorphisms	200
8.6.3	Inhibition and Induction	201
8.6.3.1	Introduction	201
8.6.3.2	Inhibition	201
8.6.3.3	Induction	203
8.7	Synergism and Potentiation	204
8.8	Biphasic Effects	204
8.9	Environmental Effects	204
8.10	Human Variation in Toxicant Metabolism	204
8.11	Summary of Toxicant Metabolism Suggested Reading	205 206
<b>9</b>	<b>Structure, Mechanism, and Regulation of Cytochromes P450</b>	<b>209</b>
	<i>John M. Seubert, Matthew L. Edin, and Darryl C. Zeldin</i>	
9.1	Introduction	209
9.2	Complexity of the Cytochrome 450 Gene Superfamily	210
9.2.1	CYP Gene Families and Subfamilies	210
9.2.2	Pseudogenes and Alternate Splice Variants	211
9.3	Cytochrome P450 Structure	214
9.4	Mechanisms of P450 Catalysis	217
9.4.1	Catalytic Cycle	217
9.4.2	Catalytic Requirements	219
9.4.3	Substrate Specificity and Overlap	219
9.4.4	Endogenous Substrates	220
9.5	Cytochrome P450 Regulation	225
9.5.1	Tissue Distribution	225
9.5.2	Constitutive and Inducible P450 Enzymes	225
9.5.3	Aromatic Hydrocarbon Receptor Induction of P450s	227
9.5.4	Phenobarbital Induction of P450s	229
9.5.5	Induction of P450s by Peroxisome Proliferators	230
9.5.6	Hormonal Regulation of P450s	230

- 9.5.7 Nutritional Regulation of P450s 233
- 9.5.8 Regulation of P450s by Cytokines 234
- 9.5.9 Regulation of P450s by Nitric Oxide 234
- 9.6 Transgenic Animal Models 235
- 9.7 Reactive Oxygen Species 235
- 9.8 Posttranslational Modification of P450s 236
- 9.9 Summary 237
- Suggested Reading 238
  
- 10 Polymorphisms in Phase I and Phase II Genes and Outcomes 239**  
*Yoshiaki Tsuji, Edward L. Croom, and Ernest Hodgson*
- 10.1 Introduction 239
- 10.2 Toxicogenetics and Single Nucleotide Polymorphisms (SNPS) 240
- 10.3 Polymorphic Cytochrome P450 and Xenobiotics Metabolism 242
- 10.3.1 CYP2A6 244
- 10.3.2 CYP2B6 245
- 10.3.3 CYP2C9 245
- 10.3.4 CYP2C19 245
- 10.3.5 CYP2D6 246
- 10.3.6 Other CYP Polymorphisms and Outcomes 247
- 10.4 Other Polymorphic Phase I Genes and Xenobiotics Metabolism 248
- 10.4.1 Alcohol Dehydrogenase 248
- 10.4.2 Aldehyde Dehydrogenase 249
- 10.4.3 Flavin-Containing Monooxygenases 249
- 10.4.4 Epoxide Hydrolase 250
- 10.4.5 Serum Cholinesterase 250
- 10.4.6 Paraoxonase 251
- 10.5 Polymorphisms: Mechanistic Classification 251
- 10.6 Methods for the Study of Polymorphisms 252
- 10.7 Phase II Gene Polymorphisms and Xenobiotics Metabolism 253
- 10.7.1 UDP-Glucuronosyl Transferases (UGTs) 253
- 10.7.2 Glutathione Synthesis and Glutathione S-Transferases 256
- 10.7.3 N-Acetyltransferases 262
- 10.7.4 Sulfotransferases 264
- 10.8 Regulation of Phase II Genes Via Antioxidant Responsive Element 267
- Suggested Reading 271
  
- 11 Cellular Transport and Elimination 273**  
*David S. Miller and Ronald E. Cannon*
- 11.1 Transport as a Determinant of Xenobiotic Action 273

11.2	Factors Affecting Membrane/Tissue Permeability	274
11.2.1	Cellular Level Transport	275
11.2.2	Tissue Level Transport	277
11.3	Xenobiotic Transporters	279
11.3.1	Transporter Families	279
11.3.1.1	ABC Transporters	280
11.3.1.2	Organic Anion Transporters (OATs; SLC22A)	283
11.3.1.3	Organic Cation Transporters (OCTs; SLC22A)	283
11.3.1.4	Organic Anion Transporters (OATPs)	284
11.3.1.5	Nucleoside and Nucleotide Transporters (SLC28 and SLC29)	284
11.3.1.6	Peptide Transporters (SLC15)	284
11.3.2	Determining the Molecular Basis for Transport in Cells and Tissues	285
11.4	Altered Xenobiotic Transport	285
11.4.1	Competition for Transport	285
11.4.2	Specific Regulation	287
11.4.2.1	Transporter Expression	287
11.4.2.2	Transporter Function	288
11.4.3	Genetic Heterogeneity	290
	Suggested Reading	290
<b>12</b>	<b>Nuclear Receptors</b>	<b>293</b>
	<i>Seth W. Kullman, William S. Baldwin, and Gerald A. LeBlanc</i>	
12.1	Introduction	293
12.2	NR Structure Function	294
12.3	Nomenclature	296
12.4	NR Transactivation	297
12.4.1	DNA Binding	297
12.4.2	RXR Heterodimerization	303
12.4.3	Coregulators	304
12.5	NRS in Toxicology	306
12.5.1	Endocrine Disruption	306
12.5.2	Estrogen Receptor (ER)	307
12.5.3	Retinoid X Receptor (RXR)	311
12.5.4	Thyroid Hormone Disruption (TR)	313
12.5.5	Peroxisome Proliferator-Activated Receptors (PPARs)	316
12.6	Endobiotic and Xenobiotic Metabolism	319
12.6.1	Pregnane X Receptor/Constitutive Androstane Receptor (PXR, CAR)	319
12.6.2	FXR/LXR Bile Acid and Cholesterol Homeostasis	321
12.7	Defining New NR Targets for Toxicity: Toxcast and Tox21	323

Reference 326  
Suggested Reading 326

- 13 Mechanisms of Cell Death 327**  
*Mac Law and Susan Elmore*
- 13.1 Introduction 327
  - 13.2 How Cells/Tissues React to “Stress” 328
    - 13.2.1 Levels of Adaptation: Physiology Versus Pathology 328
    - 13.2.2 Hypertrophy 328
    - 13.2.3 Hyperplasia 329
    - 13.2.4 Atrophy 329
    - 13.2.5 Metaplasia 329
    - 13.2.6 Dysplasia 330
  - 13.3 Cell Injury and Cell Death 330
    - 13.3.1 Causes of Cell Injury and Cell Death 331
      - 13.3.1.1 Hypoxia 331
      - 13.3.1.2 Physical Agents 332
      - 13.3.1.3 Chemicals 332
      - 13.3.1.4 Microbial Agents 332
      - 13.3.1.5 Other Causes 332
    - 13.3.2 Pathogenesis of Reversible Versus Irreversible Cell Injury 333
      - 13.3.2.1 Irreversible Injury 333
      - 13.3.2.2 Leakage Enzymes Correlate with Cell Injury 336
    - 13.3.3 Mechanisms of Irreversibility in Cell Injury 337
  - 13.4 Morphology of Cell Injury and Cell Death 339
    - 13.4.1 Cell Swelling (Hydropic Degeneration) 339
    - 13.4.2 Types of Necrosis 339
      - 13.4.2.1 Coagulative Necrosis 339
      - 13.4.2.2 Caseous Necrosis 340
      - 13.4.2.3 Fat Necrosis 341
      - 13.4.2.4 Liquefactive Necrosis 341
    - 13.4.3 Microscopic Appearance of Necrosis 341
  - 13.5 Apoptosis, Morphology, and Mechanisms 342
    - 13.5.1 Morphology of Apoptosis 343
    - 13.5.2 Mechanisms of Apoptosis 347
      - 13.5.2.1 Biochemical Features 348
      - 13.5.2.2 Extrinsic Pathway 349
      - 13.5.2.3 Perforin/Granzyme Pathway 349
      - 13.5.2.4 Intrinsic Pathway 351
      - 13.5.2.5 Execution Pathway 353
    - 13.5.3 Physiologic Apoptosis 356
    - 13.5.4 Pathologic Apoptosis 356
    - 13.5.5 Inhibition of Apoptosis 358



13.5.6	Assays for Apoptosis	359
13.5.6.1	Cytomorphological Alterations	360
13.5.6.2	DNA Fragmentation	361
13.5.6.3	Detection of Caspases, Cleaved Substrates, Regulators, and Inhibitors	362
13.5.6.4	Membrane Alterations	363
13.5.6.5	Detection of Apoptosis in Whole Mounts	363
13.5.6.6	Mitochondrial Assays	364
13.6	Other Cell Death Modalities	364
13.6.1	Autophagy	365
13.6.2	Necroptosis	366
13.6.3	Pyroptosis	366
13.6.4	Eryptosis	367
13.6.5	Anoikis	368
	Acknowledgments	369
	Reference	369
	Suggested Reading	369
<b>14</b>	<b>Mitochondrial Dysfunction</b>	<b>371</b>
	<i>Jun Ninomiya-Tsuji</i>	
14.1	Introduction	371
14.2	Mitochondrial Function	372
14.2.1	Structure: Outer and Inner Membranes	372
14.2.2	Generating High-Energy Electrons (TCA Cycle, Fatty Acid Oxidation, FADH <sub>2</sub> , and NADH)	373
14.2.3	Respiratory Chain (Complexes I, II, III, and IV and Ubiquinone, Cytochrome <i>c</i> , Proton Pump, Membrane Potential, Proton Motive Force)	374
14.2.3.1	Step 1: Complex I	375
14.2.3.2	Step 1': Complex II	375
14.2.3.3	Step 2: Complex III	376
14.2.3.4	Step 3: Complex IV	376
14.2.3.5	Step 4: ATP Synthase	376
14.2.4	Mitochondrial Membrane Pore Complex (VDAC, ANT)	377
14.2.5	Dynamic Organelle: Mitochondria (Fusion and Fission)	378
14.3	Mitochondrial Apoptosis/Necrosis	378
14.3.1	Mitochondrial Membrane Permeabilization	378
14.3.2	Caspase Activation: Effector and Initiator Caspases	379
14.3.3	Mitochondria Are “Pandora’s Box”	380
14.3.4	Interplay of Bcl2 Family (BH3-only, Bcl2, Bax/Bak)	382
14.3.5	Inner-Membrane Permeabilization	385
14.3.6	Cross Talk Between Bax/Bak and Inner-Membrane Permeabilization	386

- 14.4 Toxicant-Induced Mitochondrial Apoptosis/Necrosis 387
  - 14.4.1 Electron Transport Inhibitors 387
  - 14.4.2 Energy Transfer Inhibitors 388
  - 14.4.3 Uncouplers 388
  - References 389
- 15 Reactive Metabolites, Reactive Oxygen Species (ROS), and Toxicity 391**  
*Elizabeth L. MacKenzie and Yoshiaki Tsuji*
  - 15.1 Introduction 391
  - 15.2 Enzymes Involved in Bioactivation 394
    - 15.2.1 Phase I Oxidations 394
      - 15.2.1.1 Cytochrome P450 394
      - 15.2.1.2 Flavin-Containing Monooxygenase 397
      - 15.2.1.3 Prostaglandin Synthetase 397
    - 15.2.2 Phase II Conjugations 400
    - 15.2.3 Intestinal Microflora 402
  - 15.3 Stability of Reactive Metabolites 403
  - 15.4 Factors Affecting Metabolic Balance and Toxicity 405
    - 15.4.1 Saturation of Detoxication Pathways 405
    - 15.4.2 Enzyme Induction 405
    - 15.4.3 Genetic and Physiological Factors 406
    - 15.4.4 Metabolic Interactions 407
    - 15.4.5 DNA Adduct Formation 407
    - 15.4.6 Redox Cycling 408
  - 15.5 Reactive Oxygen Species (ROS) and Toxicity 409
    - 15.5.1 Generation and Detoxication of ROS 409
    - 15.5.2 Measurement of ROS 412
    - 15.5.3 Oxidative DNA Damage 413
    - 15.5.4 Protein Oxidation 415
    - 15.5.5 Lipid Peroxidation 417
    - 15.5.6 ROS and Human Diseases 418
    - Suggested Reading 419
- 16 DNA Damage and Mutagenesis 421**  
*Zhigang Wang*
  - 16.1 Introduction 421
  - 16.2 Endogenous DNA Damage 422
    - 16.2.1 DNA Base Mismatches 422
    - 16.2.2 Base Deamination 423
    - 16.2.3 AP Site 424
    - 16.2.4 Oxidative DNA Damage 426
    - 16.2.5 DNA Adducts Formed from Lipid Peroxidation Products 429
    - 16.2.6 DNA Methylation 432

- 16.2.7 Incorporation of Inappropriate and Damaged dNTP into DNA during Replication 432
  - 16.2.7.1 Incorporation of Uracil into DNA 432
  - 16.2.7.2 Genomic DNA of the *Bacillus subtilis* Phage PBS2 Naturally Contains Uracil instead of Thymine 433
  - 16.2.7.3 Incorporation of 8-Oxoguanine into DNA 434
- 16.3 Environmental DNA Damage 435
  - 16.3.1 DNA Damage by Ionizing Radiation 435
    - 16.3.1.1 Base Damage and Single-Strand Breaks 436
    - 16.3.1.2 Multiply Damaged Sites and Double-Strand Breaks 437
  - 16.3.2 DNA Damage by UV Radiation 438
    - 16.3.2.1 The Major UV Lesions: Cyclobutane Pyrimidine Dimers and (6-4) Photoproducts 438
    - 16.3.2.2 Minor DNA Lesions of UV Radiation 441
  - 16.3.3 DNA Damage by Chemicals 441
    - 16.3.3.1 DNA-Damaging Chemicals Without Metabolic Activation 442
    - 16.3.3.2 DNA-Damaging Chemicals That Require Metabolic Activation 445
- 16.4 Nanoparticles and DNA Damage 451
- 16.4 Concepts of Mutagenesis 453
  - 16.4.1 Definition of Terms 453
    - 16.4.1.1 General Terms 453
    - 16.4.1.2 Terms Based on Phenotypic Consequences 453
    - 16.4.1.3 Terms Based on DNA Sequence Changes 454
  - 16.4.2 Origin of Mutagenesis 455
  - 16.4.3 Biological Significance of Mutagenesis 455
- 16.5 Mechanisms of DNA Damage-Induced Mutagenesis 456
  - 16.5.1 Chromosomal Aberrations 456
  - 16.5.2 Mutagenesis Induced by DNA Double-Strand Breaks 458
  - 16.5.3 Mutagenesis Induced by DNA Base Damage 459
    - 16.5.3.1 The Major Mechanism of Base Damage-Induced Mutagenesis Is Error-Prone Translesion Synthesis 459
    - 16.5.3.2 Mechanistic Models of Translesion Synthesis 461
    - 16.5.3.3 The Y Family of DNA Polymerases 461
    - 16.5.3.4 Properties of the Y-Family DNA Polymerases 465
    - 16.5.3.5 Pol $\zeta$  Is a Major Extension Polymerase for Translesion Synthesis 466
    - 16.5.3.6 Translesion Synthesis Is Part of the DNA Damage Tolerance System 467
    - 16.5.3.7 Control of Translesion Synthesis and Mutagenesis 469
    - 16.5.3.8 The Y-Family DNA Polymerases Contain Sequence Motifs for Protein–Protein Interactions 472
    - 16.5.3.9 Translesion Synthesis Is a Complex Pathway 473
    - 16.5.3.10 Translesion Synthesis: Determining Error-Free Versus Error-Prone 475

16.5.4	Mutagenic Signatures of Selected DNA Lesions	476
16.5.4.1	AP Sites	476
16.5.4.2	UV Photoproducts	477
16.5.4.3	BPDE- $N^2$ -dG Adducts	479
16.5.4.4	The 1, $N^6$ -Ethenoadenine Adducts	479
16.5.4.5	Cisplatin	480
16.5.5	Damage-Induced Mutagenesis in Immunology: Somatic Hypermutation	480
	Suggested Reading	482
<b>17</b>	<b>DNA Repair</b>	<b>485</b>
	<i>Isabel Mellon</i>	
17.1	Introduction	485
17.2	Direct Reversal of Base Damage	487
17.2.1	UV Radiation	488
17.2.2	Alkylation Damage	491
17.3	Base Excision Repair	495
17.3.1	Glycosylases	497
17.3.1.1	Uracil	498
17.3.1.2	Alkylated Bases	499
17.3.1.3	Oxidized and Fragmented Bases	500
17.3.1.4	Pyrimidine Dimers	502
17.3.2	AP Endonucleases	502
17.3.3	Repair Synthesis and Ligation	503
17.3.4	Base Excision Repair and DNA Methylation	505
17.4	Nucleotide Excision Repair	505
17.4.1	DNA Damage Recognition	506
17.4.2	<i>E. coli</i>	507
17.4.3	Mammalian Cells	509
17.4.4	Nucleotide Excision Repair and Transcription	512
17.4.5	Human Diseases	514
17.5	Mismatch Repair	516
17.5.1	<i>E. coli</i>	518
17.5.2	Mammalian Cells	518
17.5.3	Cancer	520
17.6	Recombinational Repair	522
17.6.1	Double-Strand Break Repair in <i>E. coli</i>	522
17.6.2	Double-Strand Break Repair in Eukaryotic Cells	524
17.6.3	Interstrand Cross-Link Repair	526
17.7	DNA Repair and Chromatin Structure	528
17.7.1	Chromatin Structure	529
17.7.2	Chromatin Remodeling in DNA Repair	529
17.8	DNA Repair in Mitochondria	531

17.9	DNA Repair and Cancer	532
17.10	Summary	533
	Reference	533
	Suggested Reading	533
<b>18</b>	<b>Carcinogenesis</b>	<b>535</b>
	<i>Robert C. Smart and Jonathan R. Hall</i>	
18.1	Introduction	535
18.2	Human Cancer	537
18.2.1	Hallmarks of Cancer	540
18.2.2	Cancer Nomenclature	540
18.2.3	Causes, Incidence, and Mortality Rates	541
18.2.4	Classification of Carcinogens	545
18.3	Categorization of Agents Associated with Carcinogenesis	551
18.3.1	DNA-Damaging Agents	551
18.3.2	Nongenotoxic Agents	553
18.4	Somatic Mutation Theory	553
18.4.1	Electrophilic Theory, Metabolic Activation, and DNA Adducts	554
18.4.2	DNA Damage	558
18.4.3	Complete Carcinogenesis Model	559
18.5	Epigenetic Mechanism of Tumorigenesis	559
18.6	Multistage Tumorigenesis	560
18.6.1	Initiation–Promotion Model	561
18.6.2	Mechanisms of Tumor Promotion	563
18.7	Oncogenes	565
18.7.1	Cell Transformation: Role of Carcinogens and Oncogenes	566
18.7.2	Activation of Proto-Oncogenes to Oncogenes	567
18.7.3	Oncogenes and Signal Transduction	569
18.7.4	Oncogene Classification	570
18.7.4.1	Growth Factors as Oncogenes	570
18.7.4.2	Receptor Tyrosine Kinases as Oncogenes	571
18.7.4.3	Non-Receptor Tyrosine Kinases as Oncogenes	572
18.7.4.4	Small Guanosine Triphosphatases as Oncogenes	573
18.7.4.5	Serine/Threonine Kinases as Oncogenes	576
18.7.4.6	Transcription Factors as Oncogenes	576
18.7.4.7	Oncogenic Proteins Involved in Cell Survival	577
18.7.5	Oncogene Cooperation	577
18.8	Tumor Suppressor Genes	578
18.8.1	Retinoblastoma Gene and the Cell Cycle	580
18.8.2	Cyclin-Dependent Kinase Inhibitors and the pRB Circuit	582
18.8.3	pRB Is Inactivated in Tumorigenesis by Multiple Mechanisms	583

- 18.8.4 *p53* 584
- 18.8.5 *p14<sup>ARF</sup>* 586
- 18.9 Mutator Phenotype/DNA Stability Genes 586
- 18.10 Conclusions 587
- Reference 588
- Suggested Reading 588

## **Section 4 Molecular and Biochemical Aspects of Organ Toxicology 589**

### **19 Molecular Mechanisms of Respiratory Toxicity 591**

*James C. Bonner*

- 19.1 Introduction 591
- 19.2 Anatomy and Function of the Respiratory Tract 591
- 19.2.1 Upper Respiratory Tract as a Site of Toxicity 594
- 19.2.2 Lower Respiratory Tract as a Site of Toxicity 596
- 19.2.3 Airways of the Lower Respiratory Tract 597
- 19.2.4 Parenchyma of the Lower Respiratory Tract 599
- 19.2.5 Circulatory, Lymphatic, and Nervous System of the Lung 601
- 19.3 Toxicant-Induced Lung Injury, Remodeling, and Repair 603
- 19.3.1 Oxidative Stress and Lung Injury 605
- 19.3.2 Antioxidant Mechanisms in the Lung 608
- 19.3.3 Oxidants and Cell Signaling in the Lung 610
- 19.3.4 Respiratory Tract Injury from Inhaled Particles and Fibers 611
- 19.3.5 Particle and Fiber Deposition and Clearance 613
- 19.3.6 Respiratory Tract Injury from Gases and Vapors 616
- 19.4 Occupational and Environmental Lung Diseases 617
- 19.4.1 Pulmonary Fibrosis 617
- 19.4.2 Asthma 619
- 19.4.3 Hypersensitivity Pneumonitis 622
- 19.4.4 COPD 624
- 19.4.5 Lung Cancer 626
- Suggested Reading 627

### **20 Molecular Mechanisms of Hepatotoxicity 629**

*Supriya R. Kulkarni, Andrew D. Wallace, Sharon A. Meyer, and Angela L. Slitt*

- 20.1 Introduction 629
- 20.2 Liver Organization and Cellular Components 630
- 20.2.1 Liver Cellular Composition 631
- 20.2.1.1 Hepatocytes 631

20.2.1.2	Liver Stem Cells	632
20.2.1.3	Nonparenchymal Liver Cells	632
20.2.2	Liver Lobule and Zonal Variations	633
20.3	Acute and Chronic Hepatotoxicity	635
20.3.1	Acute Liver Injury	635
20.3.2	Chronic Liver Injury	636
20.3.3	Vascular Lesions	636
20.3.4	Neoplasia	636
20.3.5	Clinical Markers of Hepatotoxicity	637
20.4	Types of Hepatotoxicity	637
20.4.1	Fatty Liver	637
20.4.2	Fibrosis	640
20.4.3	Cholestasis	640
20.5	Mechanisms of Hepatotoxicity	643
20.5.1	Cell Type-Dependent Hepatotoxicity	643
20.5.1.1	Hepatocyte Mediated	643
20.5.1.2	Nonparenchymal Cell Population Mediated	643
20.5.1.3	Immune Cell Mediated	643
20.5.1.4	Hepatic Stellate Cell Mediated	644
20.5.1.5	Cholangiocyte Mediated	644
20.5.2	Pathways Involved in Hepatotoxicity	644
20.5.2.1	Metabolism Dependent	644
20.5.2.2	Oxidative Stress	645
20.5.2.3	Contribution of Ca <sup>2+</sup>	650
20.5.2.4	Nuclear Hormone Receptor and Transcription Factors	651
20.5.2.5	Extrahepatic Inflammation-Mediated Mechanisms	653
20.5.2.6	Epigenetic Changes	654
20.5.2.7	Developmental Origins of Liver Disease	654
20.6	Autoprotection and Protective Priming	654
20.7	Experimental Prediction of Hepatotoxicity	655
20.7.1	<i>In Vitro</i> Cell-Based Models	655
20.7.2	Animal Models	657
20.7.3	<i>In Silico</i> Models	657
20.8	Compounds Causing Liver Injury	657
20.8.1	Drugs	657
20.8.2	Ethanol	658
20.8.3	Halogenated Aliphatic Hydrocarbons	659
20.8.4	Nitrogenous Compounds	659
20.8.5	Pesticides	659
20.8.6	Natural Toxins	660
20.8.7	Toxic Metals	660
20.9	Conclusions	661
	Suggested Reading	661

<b>21</b>	<b>Molecular Mechanisms of Renal Toxicology</b>	<b>665</b>
	<i>Lawrence H. Lash</i>	
21.1	Introduction	665
21.2	Influence of Renal Structure and Function on Susceptibility to Nephrotoxicity and Renal Damage	667
21.2.1	Renal Structure and Nephrotoxicity	667
21.2.1.1	Proximal Tubules	670
21.2.1.2	Thin Descending and Thin Ascending Limbs	671
21.2.1.3	Thick Ascending Limb	671
21.2.1.4	Distal Tubule	671
21.2.1.5	Cortical Collecting Duct	672
21.2.2	Renal Physiology and Nephrotoxicity	672
21.2.3	Cellular Energetics and <i>In Vivo</i> Tissue Oxygenation	675
21.2.4	Membrane Transport and Nephrotoxicity	676
21.2.5	Bioactivation Mechanisms and Nephrotoxicity	680
21.3	Classification of Renal Injury	682
21.3.1	Acute Kidney Injury	682
21.3.1.1	Hypoperfusion or Hypofiltration	683
21.3.1.2	Direct Tubular Injury	683
21.3.1.3	Obstruction	683
21.3.1.4	Tubulointerstitial Fibrosis	683
21.3.2	Chronic Kidney Injury	683
21.4	Assessment of Renal Function in the Clinic and in Animal Models	684
21.4.1	Measurement of GFR	684
21.4.2	Urinalysis	686
21.4.2.1	Standard Urinalysis	686
21.4.2.2	Enzymuria	686
21.5	General Considerations for Choosing an Experimental Model to Study Nephrotoxicity	686
21.6	<i>In Vitro</i> Models to Study Mechanisms of Renal Injury	689
21.6.1	Isolated Perfused Kidney, Renal Slices, and Isolated Tubules and Tubule Fragments	690
21.6.2	Freshly Isolated Renal Epithelial Cells and Primary Cell Culture	690
21.6.3	Immortalized Renal Cell Lines	693
21.6.4	Human-Induced Pluripotent Stem Cells	694
21.7	General Considerations Regarding Responses to Toxicants at the Cellular Level	695
21.8	Mechanisms of Toxicant Action in the Kidneys	697
21.8.1	Pathways of Cell Death Caused by Nephrotoxicants: Necrosis, Apoptosis, and Autophagy	697



- 21.8.2 Molecular Markers of Renal Cellular Repair, Regeneration, and Proliferation 699
- 21.8.3 Use of Genomics, Proteomics, and Metabolomics in Renal Toxicology 700
- 21.8.4 Redox Status and Oxidative Stress in Renal Toxicology 701
- 21.8.5 Signaling Pathways in Renal Toxicology 701
- 21.9 Human Disease and Risk Assessment in Renal Toxicology 702
- 21.9.1 Experimental Models of Renal Disease 702
- 21.9.2 Extrapolation of Animal Data to Humans 702
- 21.10 Summary 703
- References 704
  
- 22 Molecular Mechanisms of Neurotoxicity 709**  
*Kimberly P. Keil, Marianna Stamou, and Pamela J. Lein*
- 22.1 Introduction 709
- 22.1.1 Overview of Molecular and Cellular Neurobiology 710
- 22.1.2 Overview of Mechanisms of Neurotoxicity 713
- 22.2 Neurotransmission 715
- 22.2.1 Overview of Transmission Toxicity 715
- 22.2.2 Molecular Mechanisms of Neurotoxicity Targeting Electrical Neurotransmission 716
- 22.2.3 Molecular Mechanisms of Neurotoxicity Targeting Chemical Neurotransmission 720
- 22.3 Inter- and Intracellular Signaling 724
- 22.3.1 Overview of Inter- and Intracellular Signaling in the Nervous System 724
- 22.3.2 Modulation of Intracellular and Autocrine Signaling by Polychlorinated Biphenyls (PCBs) 725
- 22.3.3 Modulation of Intracellular and Paracrine Signaling by Lead (Pb) 732
- 22.4 Excitotoxicity 736
- 22.4.1 Overview of Excitotoxicity 736
- 22.4.2 Chemical-Induced Excitotoxicity 739
- 22.5 Protein Modifications 742
- 22.5.1 Overview of Protein Modifications 742
- 22.5.2 Chemical-Induced Protein Modifications 742
- 22.5.3 Chemical-Induced Protein Aggregation 744
- 22.6 Neuroinflammation 747
- 22.6.1 Overview of Neuroinflammation 747
- 22.6.2 Cellular Mediators of Neuroinflammatory Signaling 748
- 22.6.3 Air Pollution Triggers Neuroinflammation 751
- 22.6.4 Lipopolysaccharide-Induced Neuroinflammation 756

- 22.6.5 Neuroinflammatory Effects of MPTP 757
- 22.6.6 Challenges in Understanding Neuroinflammatory Mechanisms of Neurotoxicity 757
- 22.7 Epigenetics 758
  - 22.7.1 Overview of Epigenetic Mechanisms 758
  - 22.7.2 Epigenetic Mechanisms of PCB Neurotoxicity 762
  - 22.7.3 Modulation of the Epigenome by Bisphenol A (BPA) 764
  - 22.7.4 The Epigenetics of Lead (Pb) Neurotoxicity 765
  - 22.7.5 Critical Gaps in Understanding Epigenetic Mechanisms of Neurotoxicity 766
- 22.8 Concluding Remarks 767
  - Suggested Reading 769
  
- 23 Molecular Mechanisms of Immunotoxicity 773**  
*Tai L. Guo, Joella Xu, Yingjia Chen, Daniel E. Lefever, Guannan Huang, and David A. Lawrence*
  - 23.1 Introduction and Overview of the Immune System 773
    - 23.1.1 Immune Cells and Their Development (Hematopoiesis) 774
    - 23.1.2 Innate and Adaptive Immune Cells and Their Activities 778
  - 23.2 Immune Hypersensitivities and Autoimmune Disease 788
    - 23.3 Mucosal Immunity, the Microbiome, and Food Allergies 791
      - 23.3.1 Mucosal Immunity 791
      - 23.3.2 The Microbiota 793
      - 23.3.3 The Microbiota's Role in Immunotoxicology 795
      - 23.3.4 Food Allergies 796
    - 23.4 Molecular Immunotoxicology of Environmental Stressors 801
      - 23.4.1 Physical Stressors 801
      - 23.4.2 Chemical Stressors 804
        - 23.4.2.1 Metals 804
        - 23.4.2.2 Cigarette Smoke 805
        - 23.4.2.3 Pesticides and Other Organic Compounds 807
        - 23.4.2.4 Endocrine-Disrupting Chemicals 809
      - 23.4.3 Psychological Stressors 814
    - 23.5 Methods for Assessing Immunotoxicology 815
    - 23.6 Summary 817
      - References 817
  
  - 24 Molecular Mechanisms of Reproductive Toxicity 823**  
*Ayelet Ziv-Gal, Catheryne Chiang, and Jodi Anne Flaws*
    - 24.1 Introduction 823
    - 24.2 Organization of the Reproductive System: Sexual Differentiation 825
    - 24.3 Neuroendocrine Regulation of Reproduction 826

24.4	Female Reproductive System	829
24.4.1	The Ovary	829
24.4.1.1	Female Germ Cells and Establishment of the Ovarian Reserve	829
24.4.1.2	Folliculogenesis in the Cycling Ovary	830
24.4.1.3	Steroidogenesis in the Adult Cycling Ovary	833
24.4.2	Ovulation and Luteinization	835
24.4.3	Fertilization	836
24.4.4	Uterus and Implantation	837
24.4.5	The Placenta	837
24.4.6	Parturition	838
24.4.7	Lactation	839
24.5	Toxicity in the Male Reproductive System	840
24.5.1	The Testes: Spermatogenesis and Steroidogenesis	840
24.5.2	Efferent Ducts and Epididymis	844
24.5.3	Accessory Sex Glands	845
24.6	Transgenerational Effects on Reproduction	845
24.7	Summary	846
	References	847
<b>25</b>	<b>Molecular Mechanisms of Developmental Toxicity</b>	<b>851</b>
	<i>Antonio Planchart</i>	
25.1	Introduction	851
25.2	Overview of Development and General Principles	852
25.2.1	Model and Non-Model Organisms in Developmental Biology	853
25.2.2	Early Development: Cleavage, Gastrulation, and Axis Formation	853
25.2.3	Neurodevelopment	855
25.2.4	Neural Crest	856
25.2.5	Segmentation and Organ Development	857
25.2.6	Limb Development	857
25.2.7	Fetal Period	858
25.3	Wilson's Principles of Teratology	859
25.3.1	Genetic Influences on Teratogen Susceptibility: Gene–Gene and Gene-by Environment Interactions	860
25.3.1.1	Interspecies Differences in Susceptibility	861
25.3.1.2	Intraspecies Differences in Susceptibility: Alleles and Epigenetics	861
25.3.2	Susceptibility Windows	861
25.3.3	Teratogenic Agents Act through Specific Mechanisms	863
25.3.4	Manifestations of Abnormal Development	864
25.3.5	Physicochemical Properties of Teratogens and Their Role in Determining Developmental Toxicity	866

- 25.3.6 Dosage and Severity 867
- 25.4 Selected Examples of Developmental Toxicants 868
  - 25.4.1 Anticonvulsants 868
  - 25.4.2 Alcohol 869
  - 25.4.3 Cyclophosphamide 869
  - 25.4.4 Diethylstilbestrol 870
  - 25.4.5 Retinoids 871
  - 25.4.6 Thalidomide 872
- 25.5 Advances in Developmental Toxicology Methods 873
  - 25.5.1 High-Throughput Screens 873
  - 25.5.2 Computational Developmental Toxicology 874
- 25.6 Summary 875
  - References 875

## **Section 5 Emerging Areas in Molecular and Biochemical Toxicology 877**

- 26 Computational and Molecular Approaches to Risk Assessment 879**  
*Richard S. Judson, John Wambaugh, Kristin Isaacs, and Russell S. Thomas*
  - 26.1 Introduction 879
    - 26.1.1 Hazard Identification/HTS 880
    - 26.1.2 Potency Quantification/HTTK 880
    - 26.1.3 Exposure Estimation/HTE 881
    - 26.1.4 Estimation of Uncertainty and Variability 881
    - 26.1.5 Estimation of Margins of Exposure 882
  - 26.2 High-Throughput Bioactivity 883
  - 26.3 High-Throughput Toxicokinetics 889
    - 26.3.1 Overview of the HTTK Approach 891
    - 26.3.2 Estimating Population Variability in HTTK 895
    - 26.3.3 Estimating Uncertainty in HTTK 895
  - 26.4 High-Throughput Exposure 897
    - 26.4.1 Basic Approach to HTE 898
    - 26.4.2 Estimating Uncertainty in HTE 904
  - 26.5 Summary 905
    - References 906
- 27 Nanotoxicology 909**  
*James C. Bonner*
  - 27.1 Introduction 909
  - 27.2 Naturally Occurring and Unintentional Nanoparticles 913
  - 27.3 Engineered Nanomaterials 913
    - 27.3.1 Carbon Nanomaterials 913

27.3.2	Metal and Metal Oxide Nanoparticles	914
27.3.3	Organic Biodegradable Nanoparticles	914
27.3.4	Functionalization of Nanoparticles	914
27.4	Exposure to Nanoparticles	915
27.4.1	Dermal Exposure	915
27.4.2	Inhalation	916
27.4.3	Oral Exposure	918
27.5	Protein Corona Formation on Nanoparticles	918
27.6	Nanoparticle Interactions with Biological Barriers	920
27.6.1	Epithelial–Endothelial Barriers in the Lung and GI Tract	920
27.6.2	Blood–Brain Barrier	920
27.6.3	Placental Barrier	921
27.7	Degradation and Clearance	921
27.8	Adverse Effects of Nanoparticles	923
27.8.1	Molecular Mechanisms of Nanoparticle Toxicity	924
27.8.2	Immunotoxicity	926
27.8.3	Pulmonary Fibrosis	926
27.8.4	Exacerbation of Asthma	927
27.8.5	Lung Cancer	927
27.8.6	Cardiovascular Toxicity	928
27.8.7	Hepatotoxicity	928
27.8.8	Neurotoxicity	928
27.9	Nanomedicine	929
27.9.1	Nanotherapy	929
27.9.2	Nanoparticles in Biomedical Imaging	930
27.9.3	Nanotherapy-Associated Toxicity	931
27.10	Life Cycle of Nanoparticles in the Environment	931
	Suggested Reading	931
<b>28</b>	<b>Developmental Origins of Health and Disease</b>	<b>933</b>
	<i>Michael Cowley</i>	
28.1	Introduction	933
28.2	Historical Perspective: Birth Weight and Early Life Nutrition in Adult Health	934
28.3	The Effects of Environmental Chemicals on the Programming of Adult Health	935
28.3.1	Obesity	935
28.3.2	Fertility	936
28.3.3	Brain Development, Behavior, and Neurodegeneration	937
28.4	Biological Mechanisms	938
28.4.1	Hormones and Endocrine-Disrupting Compounds in Development	938
28.4.2	Epigenetics	939

28.4.3	Multigenerational and Transgenerational Effects	941
28.5	Conclusions	943
	Suggested Reading	943
<b>29</b>	<b>Exposome</b>	<b>945</b>
	<i>Stephen M. Rappaport</i>	
29.1	Introduction	945
29.1.1	Genes Versus the Environment	945
29.1.2	Characterizing Genes and Exposures	946
29.1.3	Exposures of Regulatory Importance	946
29.1.4	Introducing the Exposome	948
29.2	The Exposome and Disease Pathways	949
29.2.1	Choosing the Best Omes	949
29.3	The Blood Exposome	951
29.3.1	Blood Concentrations	951
29.3.2	The Chemical Space	953
29.3.3	Connections to Health Effects	953
29.3.4	Connections to Metabolic Pathways	956
29.3.5	Implications for Epidemiology and Systems Biology	956
29.4	The Exposome and Social Factors	957
29.4.1	Relationships with Exogenous Exposures	957
29.4.2	Relationships with Endogenous Exposures	958
29.4.3	Finding Causal Pathways	958
29.5	Discovering Causes of Disease	958
29.5.1	Performing EWAS	958
29.5.2	Using Biospecimens from Prospective Cohorts	960
29.5.3	Untargeted and Semi-Targeted Designs	960
29.6	The Future of the Exposome	961
29.6.1	Advances in Technology	961
29.6.2	Moving Beyond 300 Environmental Chemicals	961
29.6.3	Future Research and Training	962
	Acknowledgments	962
	References	963
	<b>Index</b>	<b>969</b>